Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* COPD exacerbation~* Invasive mechanical ventilation and sedation for a planned duration of at least 24 hours~* Consent~* Age ≥ 18 years~* Affiliation or beneficiary of a social security scheme~Exclusion Criteria :~* Contraindication to the administration of sevoflurane (personal or family history of malignant hyperthermia, allergy or halogenated anesthetic accident, chronic myopathy, halogenated toxic hepatitis, uncontrolled intracranial hypertension, unexplained leukocytosis after anesthesia with a halogenated agent)~* Contraindication to the administration of propofol (known hypersensitivity to propofol, soy, peanut or any of the excipients of the emulsion, antecedent of Propofol Related Infusion Syndrome)~* Refusal of consent~* Guardianship~* Age \< 18 years~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevoflurane group (Type: EXPERIMENTAL): None
- Propofol group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).